NGVT · Ingevity Corporation

Ingevity's Q1 2026 results showed net sales growth of 4% to $258.0 million, primarily from annual pricing actions in Performance Materials and Pavement Technologies plus favorable FX, though GAAP net income fell to $23.4 million due to $22.7 million pre-tax special charges including a $16.2 million BASF litigation settlement. Adjusted metrics improved with earnings up 12% to $41.4 million and EPS to $1.15, reflecting stronger execution amid volatility. Adjusted EBITDA held flat at $91.5 million as pricing and volume gains offset weaker Road Markings performance and lower Advanced Polymer utilization. Segment highlights included Performance Materials sales up 6% to $155.4 million with EBITDA margin expanding 230bps to 59.2% from better mix toward hybrids and inventory builds; Performance Chemicals EBITDA dropped to $0.6 million due to Road Markings pressures; Advanced Polymer sales rose 5% but EBITDA halved from prior inventory dynamics. CEO Dave Li highlighted execution, early divestitures enabling $52 million share repurchases, and reaffirmed FY2026 outlook adjusted for Industrial Specialties (sold Jan 1 for ~$93M) and Road Markings (sold Apr 15 for ~$65M net) exits. Guidance targets net sales $1.05-1.15B, adjusted EBITDA $370-395M, EPS $4.70-5.20, and FCF $215-245M excluding BASF payment, with plans to delever to 2.0-2.5x and return cash to shareholders. Net leverage stable at 2.6x supports capital allocation flexibility post-divestitures.